Weekly Ophthalmic Newsletter
Ophthalmology Breaking News
Ophthalmology Breaking News (OBN) is the international source for ophthalmic industry news.
Welcome to this week’s OBN LinkedIn Newsletter!
This week, we have exciting updates on new FDA authorizations, groundbreaking research, corporate acquisitions, and impactful clinical trial results. Let’s take a closer look at the latest advancements in ophthalmology!
1. LumiThera Receives FDA Authorization for Valeda Treatment for Dry AMD
LumiThera has received FDA authorization for its Valeda Light Delivery System, a photobiomodulation therapy designed to treat dry age-related macular degeneration (AMD).
Valeda provides non-invasive, light-based treatment that targets cellular health and improves retinal function, offering hope for patients with limited treatment options for this progressive disease. FDA approval marks a significant milestone for LumiThera and expands available therapies for patients with dry AMD in the U.S.
2. Genentech’s Phase 4 Study Confirms Vabysmo’s Efficacy in Diverse DME Populations
Phase 4 trial results for Roche’s Vabysmo show strong effectiveness in treating diabetic macular edema (DME).
The drug demonstrated significant improvement in vision and reduction in retinal thickness, providing a robust solution for patients with DME. Vabysmo’s dual mechanism of action targets two disease pathways, offering comprehensive benefits for retinal health. This positive outcome reinforces Vabysmo’s role in the standard care for DME and highlights its potential for broader applications.
3. FDA Clears IND Application for HG202 Gene Therapy in Wet AMD
The FDA has cleared the Investigational New Drug (IND) application for HG202, a novel gene therapy aimed at treating wet age-related macular degeneration (AMD).
Developed to target vascular growth in the retina, HG202 offers a promising approach to managing AMD through a single administration, reducing the frequency of treatments. This clearance is an essential step toward clinical trials, bringing the potential of a durable gene therapy treatment for AMD one step closer.
4. Johnson & Johnson Unveils New Data on Acuvue Oasys Max
Johnson & Johnson Vision has shared new data on Acuvue Oasys Max contact lenses, showing enhanced performance in maintaining moisture and comfort for extended wear.
The findings reveal that these lenses improve vision stability even in demanding conditions, making them ideal for users who spend long hours on digital devices or in dry environments. This innovation in contact lens technology emphasizes the company’s commitment to addressing modern vision needs.
5. Cencora Acquires Retina Consultants of America
Cencora (formerly AmerisourceBergen) has announced its acquisition of Retina Consultants of America, a leading retina care provider network in the U.S.
This acquisition aligns with Cencora's strategy to expand its healthcare solutions and strengthen its presence in specialized eye care. The integration of RCA’s network and expertise will enable Cencora to offer enhanced resources and support for retina specialists, ultimately benefiting patients with complex retinal conditions.
6. Positive Phase 3 Results for APP13007 in China
APP13007, a topical corticosteroid developed by Formosa Pharmaceuticals, has shown positive results in its Phase 3 trial in China for treating post-surgical inflammation.
The trial results demonstrated effective reduction in inflammation with a favorable safety profile, potentially making APP13007 a valuable treatment for post-operative eye care. This achievement brings Formosa Pharmaceuticals closer to providing a reliable anti-inflammatory option for post-surgical recovery.
Stay Updated: For more insights on the latest developments in ophthalmology, visit our website and follow us for regular updates.
Thank you for staying connected with OBN!
Enjoy our LinkedIn updates? You can also stay updated with the latest news via email.